Welcome to the Myr GmbH company's website
MYR GmbH is focused on development of Myrcludex B, a first-in-class drug for treatment of chronic hepatitis B (HBV) and chronic hepatitis delta (HDV) infection. Myrcludex B inhibits the essential HBV receptor and prevents spread of HBV in the liver. HDV is using HBV envelope to infect liver cells and may be targeted by Myrcludex B either. The product has a landscape-changing potential in both indications.
- Management Team
- Technology & Mode Of Action
- Clinical Advisory Board
- Clinical Trails / Pipeline